Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Ascites (2)
- Cirrhosis (2)
- Hepatorenal syndrome (2)
- Acute kidney injury (1)
- Acute liver failure (1)
-
- Albumin (1)
- Anticoagulation (1)
- Creatinine (1)
- Cryptogenic cirrhosis (1)
- Hepatology (1)
- Hepatorenal cocktail (1)
- Interventional radiology (1)
- Midodrine (1)
- N-acetylcysteine (1)
- Non-acetaminophen-induced (1)
- Octreotide (1)
- PVT (1)
- Pancreatic cancer (1)
- Portal hypertension (1)
- Portal vein thrombosis (1)
- Radiology (1)
- Relapse (1)
- Substance Abuse (1)
- TIPS (1)
- Terlipressin (1)
- Transjugular intrahepatic portosystemic shunt (1)
- Variceal bleeding (1)
- Varices (1)
Articles 1 - 5 of 5
Full-Text Articles in Hepatology
Substance Abuse Relapse Is Not About Willpower But Is The Culmination Of Psychological And Socioeconomic Stress, Paul A. Steffes
Substance Abuse Relapse Is Not About Willpower But Is The Culmination Of Psychological And Socioeconomic Stress, Paul A. Steffes
Clinical Research in Practice: The Journal of Team Hippocrates
The author reflects on the impact of non-judgmental listening on patient care outcomes.
Interventional Treatment With The Transjugular Intrahepatic Portosystemic Shunt (Tips) Procedure May Offer A Preferable Alternative To Systemic Anticoagulation In Patients With Cirrhosis And Portal Vein Thrombosis, Molly N. Pantelic
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical decision report appraising:
Wang Z, Jiang MS, Zhang HL, et al. Is post-tips anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial. Radiology. 2016;279(3):943-951. https://doi.org/10.1148/radiol.2015150369
for a patient with cryptogenic cirrhosis, gastroesophageal varices, pancreatic cancer, and portal vein thrombosis.
Combination Octreotide, Midodrine, And Albumin May Improve Survival In Patients With Hepatorenal Syndrome, But The Evidence Is Weak, Jacob Szafranski
Combination Octreotide, Midodrine, And Albumin May Improve Survival In Patients With Hepatorenal Syndrome, But The Evidence Is Weak, Jacob Szafranski
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009 Aug;43(7):680-5. doi: 10.1097/MCG.0b013e318188947c
It Is Reasonable To Treat Patients With Type 1 Hepatorenal Syndrome With Midodrine And Octreotide, William Kane
It Is Reasonable To Treat Patients With Type 1 Hepatorenal Syndrome With Midodrine And Octreotide, William Kane
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi: 10.1007/s10620-006-9312-0
Salvage Therapy For Non-Acetaminophen-Induced Acute Liver Failure Includes N-Acetylcysteine, David Robinson
Salvage Therapy For Non-Acetaminophen-Induced Acute Liver Failure Includes N-Acetylcysteine, David Robinson
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864. doi: 10.1053/j.gastro.2009.06.006